GSK
822 hedge funds and large institutions have $9.91B invested in GSK in 2023 Q2 according to their latest regulatory filings, with 80 funds opening new positions, 290 increasing their positions, 275 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
822
Holders Change
+17
Holders Change %
+2.11%
% of All Funds
12.96%
Holding in Top 10
11
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-15.38%
% of All Funds
0.17%
New
80
Increased
290
Reduced
275
Closed
58
Calls
$207M
Puts
$133M
Net Calls
+$73.9M
Net Calls Change
-$27.5M
Top Buyers
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$197M |
| 2 |
Primecap Management
Pasadena,
California
|
+$67.7M |
| 3 |
PTC
Provident Trust Company
Waukesha,
Wisconsin
|
+$64.2M |
| 4 |
Morgan Stanley
New York
|
+$63.8M |
| 5 |
Holocene Advisors
New York
|
+$61.8M |
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$105M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$93.8M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$56.1M |
| 4 |
Renaissance Technologies
New York
|
-$43M |
| 5 |
Goldman Sachs
New York
|
-$35.8M |
